Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Brief Summary: Primary Objective:

To compare the effect of alirocumab with placebo on the occurrence of cardiovascular (CV) events (composite endpoint of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and non-fatal ischemic stroke, unstable angina (UA) requiring hospitalization) in participants who experienced an acute coronary syndrome (ACS) event 4 to 52 weeks prior to randomization and were treated with evidence-based medical and dietary management of dyslipidemia.

Secondary Objectives:

* To evaluate the effect of alirocumab on secondary endpoints (any CHD event , major CHD event, any CV event, composite of all cause mortality/non-fatal MI/non-fatal ischemic stroke, CHD deaths, CV deaths, all cause mortality).
* To evaluate the safety and tolerability of alirocumab.
* To evaluate the effect of alirocumab on lipid parameters.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: LMT | Arm Label: Alirocumab 75 mg Q2W/Up to 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: LMT | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: LMT; Assigned to Arm(s): Alirocumab 75 mg Q2W/Up to 150 mg Q2W, Placebo
B: Arm Label: Bococizumab (PF-04950615; RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615; RN316) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bococizumab (PF-04950615; RN316); Assigned to Arm(s): Bococizumab (PF-04950615; RN316) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Evolocumab; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab
D: Arm Label: Atorvastatin 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Placebo | Arm Label: Ezetimibe 10 mg + Atorvastatin 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Ezetimibe, Drug: Placebo | Arm Label: Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Atorvastatin, Drug: Placebo | Arm Label: Atorvastatin 80 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Placebo | Arm Label: Rosuvastatin 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin, Drug: Placebo | Arm Label: Ezetimibe 10 mg + Atorvastatin 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Ezetimibe, Drug: Placebo | Arm Label: Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Atorvastatin, Drug: Placebo | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg, Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg, Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg, Atorvastatin 40 mg, Atorvastatin 80 mg, Ezetimibe 10 mg + Atorvastatin 20 mg, Ezetimibe 10 mg + Atorvastatin 40 mg | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe 10 mg + Atorvastatin 20 mg, Ezetimibe 10 mg + Atorvastatin 40 mg | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin 40 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg, Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg, Atorvastatin 40 mg, Atorvastatin 80 mg, Ezetimibe 10 mg + Atorvastatin 20 mg, Ezetimibe 10 mg + Atorvastatin 40 mg, Rosuvastatin 40 mg

Answer: A